scholarly journals ASCO 2021 highlights head and neck cancer: nasopharyngeal carcinoma

2021 ◽  
Author(s):  
Thorsten Fuereder
Keyword(s):  
Head And Neck Cancer ◽  
High Risk ◽  
Nasopharyngeal Carcinoma ◽  
Standard Of Care ◽  
Treatment Intensification ◽  
First Line ◽  
Open Questions ◽  
Virtual Meeting ◽  
Metastatic Setting ◽  
Line Standard

SummaryDuring the ASCO 2021 virtual meeting, multiple clinically relevant studies were presented addressing open questions regarding the therapy of nasopharyngeal carcinomas (NPC): Is immunotherapy plus chemotherapy the new first line standard of care for patients in the recurrent/metastatic setting? Is adjuvant therapy with capecitabine in high risk NPC patients post chemoradiation (CRT) beneficial? Is there a role for treatment intensification by adjuvant metronomic capecitabine in NPC patients post induction chemotherapy and CRT? This article summarizes the most significant NPC studies presented at the ASCO 2021 virtual meeting and discusses the data in the context of the current literature.

scholarly journals ASCO virtual meeting 2020: highlights head and neck cancer

2021 ◽  
Author(s):  
Thorsten Fuereder
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Locally Advanced ◽  
Standard Of Care ◽  
Open Questions ◽  
Cancer Field ◽  
Virtual Meeting ◽  
Metastatic Setting ◽  
Risk Patients

SummaryAt the ASCO 2020 virtual meeting, multiple clinically relevant studies were presented addressing open questions in the head and neck cancer field: Are de-escalation strategies feasible in low risk patients? What is the appropriate platinum dose in combination with radiotherapy in high-risk patients suffering from locally advanced disease? Is immunotherapy the first line standard of care for all patient in the recurrent/metastatic setting? This article summarizes the most significant head and neck cancer studies presented at the ASCO 2020 virtual meeting and discusses the data in the context of the current literature.

scholarly journals Teprotumumab Treatment for Thyroid-Associated Ophthalmopathy

2020 ◽  
Vol 9 (Suppl. 1) ◽  
pp. 31-39
Author(s):  
Terry J. Smith
Keyword(s):  
Paradigm Shift ◽  
Vision Loss ◽  
Standard Of Care ◽  
Autoimmune Process ◽  
First Line ◽  
Thyroid Associated Ophthalmopathy ◽  
The Us ◽  
Fundamental Research ◽  
Line Standard

<b><i>Background:</i></b> Thyroid-associated ophthalmopathy (TAO), an autoimmune process affecting the tissues surrounding the eye, most commonly develops in individuals with Graves’ disease. It is disfiguring, can cause vision loss, and dramatically lessens the quality of life in patients. There has been an absence of approved medical therapies for TAO with proven effectiveness and safety in multicenter, placebo-controlled, and adequately powered clinical trials. <b><i>Summary:</i></b> The following is a brief overview of the rationale for developing a monoclonal antibody inhibitor of the insulin-like growth factor-I receptor into a treatment for TAO. This area of fundamental research has yielded an effective and safe medication, namely teprotumumab, based on two multicenter, placebo-controlled trials. Teprotumumab, marketed as Tepezza, has been approved recently by the US Food and Drug Administration for the treatment of TAO. Given its remarkable effectiveness, Tepezza is poised to become the first-line standard of care for TAO. <b><i>Key Messages:</i></b> Introduction of Tepezza into our armamentarium of therapeutic strategies for TAO represents a paradigm shift in the management of the disease. I proffer that the drug will replace glucocorticoids as a first-line treatment for TAO.

Efficacy of trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (MBC) previously treated with pertuzumab (P).

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 1023-1023 ◽  
Author(s):  
Ander Urruticoechea ◽  
Seock-Ah Im ◽  
Montserrat Munoz ◽  
Jose Baselga ◽  
Denise A. Yardley ◽  
...  
Keyword(s):  
Metastatic Breast ◽  
Standard Of Care ◽  
Phase Iii ◽  
Clinical Activity ◽  
Limited Data ◽  
First Line ◽  
Previously Treated ◽  
Phase Iii Studies ◽  
Line Standard ◽  
Clinical Trial Information

1023 Background: T-DM1 was approved for pts with HER2+ MBC previously treated with trastuzumab (H) and a taxane based on the phase III EMILIA study. P in combination with H + docetaxel (T) later became the first-line standard of care for HER2+ MBC, but there are limited data on T-DM1 efficacy in pts who previously received P. We present exploratory efficacy results from pts treated with T-DM1 any time after P from 2 phase III studies: CLEOPATRA and PHEREXA. Methods: CLEOPATRA (NCT00567190) and PHEREXA (NCT01026142) are randomized, 2-arm trials evaluating P-based regimens for HER2+ MBC. CLEOPATRA studies H + T + P vs HT + placebo in pts with no prior anti-HER2 treatment (tx) or chemotherapy for MBC, while PHEREXA studies H + capecitabine (C) +/− P in pts who progressed during/after previous H tx for MBC. We assessed overall survival (OS) in an exploratory analysis of pts who either received or did not receive T-DM1 at any time after discontinuing study-assigned tx in CLEOPATRA or PHEREXA. Results: Of 408 pts who received HTP in CLEOPATRA and 228 pts who received HCP in PHEREXA, 32 and 43 pts received subsequent T-DM1, respectively (Table). Median duration of T-DM1 tx was 7.1 mo (range 0−44) and 4.2 mo (range 0−22), respectively, and median time from discontinuation of P to start of T-DM1 was 3.5 mo (range 1−47) and 10.6 mo (range 1−28). Conclusions: Although data are limited in these exploratory analyses, our results provide additional evidence of T-DM1 clinical activity in pts with HER2+ MBC who progressed on prior P + H, a finding with real-world implications. Clinical trial information: NCT00567190, NCT01026142. [Table: see text]

scholarly journals PS01.59: CheckMate 370: A Master Protocol of Phase 1/2 Studies of Nivolumab as Maintenance or First-Line ± Standard-of-Care Therapies in Advanced NSCLC

2016 ◽  
Vol 11 (11) ◽  
pp. S307 ◽  
Author(s):  
George Blumenschein ◽  
Jason Chandler ◽  
Edward B. Garon ◽  
David Waterhouse ◽  
Jonathan W. Goldman ◽  
...  
Keyword(s):  
Advanced Nsclc ◽  
Phase 1 ◽  
Standard Of Care ◽  
First Line ◽  
Line Standard

The choice of first-line therapy in advanced Hodgkin lymphoma: Retrospective comparison of ABVD and escalated BEACOPP regimen

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 8063-8063
Author(s):  
W. Jurczak ◽  
D. Krochmalczyk ◽  
A. Giza ◽  
J. Węgrzyn ◽  
M. Sobocinski ◽  
...  
Keyword(s):  
High Risk ◽  
Clinical Stage ◽  
Poor Response ◽  
Initial Response ◽  
Response Assessment ◽  
Poor Responders ◽  
Treatment Intensification ◽  
First Line ◽  
First Line Therapy ◽  
Study Results

8063 Background: HD patients with high risk have a relatively poor prognosis with less than 50% 5-year overall survival (OS) if treated with ABVD regimen. Methods: Therapy results of all 105 patients with advanced HL (CS IIBX -IV) treated from diagnosis at our Department in the last decade, are presented. The choice of initial 3 cycles between ABVD and escalated BEACOPP was done at the patients preferal and physician's adivice. Further 3 chemotherapy cycles depended on initial response assessment: poorly responding ABVD treated patients were offered therapy escalation. Patients with a good response (over 80% regression) after the first 3 cycles were later treated with ABVD. EFS and OS were primary endpoints of the study. Results: We divided patients into 2 treatment groups, depending on the first 3 cycles (escalated BEACOPP n = 57 or ABVD n = 48). Poor response resulting in therapy intensification was not considered as an event defined only as a relapse or progression during therapy. There was a statistically insignificant imbalance between the risk factor distribution with less favorable prognosis in patients treated with esc BEACOPP: 38 % of pts in IV th clinical stage (as compared to 31% in ABVD group), 3,08 EORTC risk factors (as compared to 2,64 in ABVD group) and 2,19 according to German Hodgkin Study Group (1.93 respectively). Increased toxicity of esc BEACOPP regimen was due to grade 3/4 cytopaenia (present in all patients) resulting in more infection episodes (according to WHO scale stage 3 - 16 pts , stage 4 - 8 pts; in ABVD group, 2 and 1 pt respectively). There were no treatment related mortalities. In esc BEACOPP projected 5 y OS was 96% and EFS 89% , which is comparable to GHSG results. 5 y OS and EFS in ABVD group are 87% and 66% respectively. The difference in EFS is statistically significant (p< 0.05). Conclusions: In our study we checked the feasibility of esc BEACOPP regimen in high risk HD pts. The results show the importance of the intensity of the first line approach. In the poor responders after the initial 3 cycles, even early treatment intensification, didn’t improve the outcome. De-escalation of therapy after the first 3 cycles, in good responders, didn’t make OS and EFS inferior to GHSG results in which they recommend 6 cycles of esc BEACOPP therapy. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document